Ser29
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser29  -  CTNNB1 (human)

Site Information
VsHWQQQsyLDsGIH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3075000

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 ) , mutation of modification site ( 6 , 7 ) , phospho-antibody ( 6 , 7 ) , western blotting ( 6 , 7 )
Disease tissue studied:
breast cancer ( 7 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , gastric cancer ( 2 , 4 , 5 ) , gastric carcinoma ( 2 , 4 , 5 ) , neuroblastoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
WNT1 (human) ( 7 )
Kinases, in vitro:
CK2A2 (human) ( 6 )
Treatments:
lithium ( 7 )

Downstream Regulation
Effects of modification on CTNNB1:
protein degradation ( 6 )
Effects of modification on biological processes:
cell motility, altered ( 6 )
Induce interaction with:
CTNNA1 (human) ( 6 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Possemato A (2011) CST Curation Set: 11913; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Guo A (2010) CST Curation Set: 10551; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Moritz A (2010) CST Curation Set: 9790; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Moritz A (2010) CST Curation Set: 9060; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Bek S, Kemler R (2002) Protein kinase CKII regulates the interaction of beta-catenin with alpha-catenin and its protein stability. J Cell Sci 115, 4743-53
12432063   Curated Info

7

van Noort M, van de Wetering M, Clevers H (2002) Identification of two novel regulated serines in the N terminus of beta-catenin. Exp Cell Res 276, 264-72
12027456   Curated Info